Sunshine Biopharma (NASDAQ: SBFM) reported Q4 2023 earnings per share (EPS) of -$5.70, up 96.2% year over year. Total Sunshine Biopharma earnings for the quarter were -$1.25 million. In the same quarter last year, Sunshine Biopharma's earnings per share (EPS) was -$150.00.
As of Q2 2024, Sunshine Biopharma's earnings has grown year over year. Sunshine Biopharma's earnings in the past year totalled -$4.51 million.
What was SBFM's revenue last quarter?
Sunshine Biopharma (NASDAQ: SBFM) reported Q4 2023 revenue of $7.68 million up 94.94% year over year. In the same quarter last year, Sunshine Biopharma's revenue was $3.94 million.
What was SBFM's revenue growth in the past year?
As of Q2 2024, Sunshine Biopharma's revenue has grown 454.42% year over year. This is 444.43 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 9.98%. Sunshine Biopharma's revenue in the past year totalled $24.09 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.